New Trends,is a critical tool in immunological research

The CD35 blocking peptide stands as a critical tool in immunological research, specifically designed to interact with and modulate the function of CD35, also known as complement receptor 1 (CR1). This peptide plays a significant role in experiments aimed at understanding the intricate mechanisms of the complement system and its interaction with cellular components. The primary function of CD35 is to serve as the cellular receptor for C3b and C4b, the most important components of the complement system, which are crucial for immune complex clearance and the regulation of inflammatory responses.

CR1 (CD35) is a transmembrane complement regulatory protein that is widely expressed on various hematopoietic cells, including erythrocytes, leukocytes, and platelets. It is also found on glomerular podocytes and follicular dendritic cells. This broad expression pattern underscores its importance in diverse immunological processes, ranging from innate and adaptive immune responses to the clearance of pathogens and immune complexes. The protein is a receptor for complement components C3b and C4b and regulates the activity of the complement cascade. CD35 binds complement C3b, C4b, or iC3, and iC4, and plays important roles in both innate and adoptive immune response via mediating phagocytosis.

The CD35 blocking peptide is typically generated from the immunogen used to create anti-CD35 antibodies. It is essentially the original antigen used during polyclonal antibody generation. This peptide is then used to block Anti-CD35 Antibody (MBS8247931) reactivity and can be easily employed as a negative control in experiments involving anti-CD35 antibodies. Its application ensures that observed effects are specific to the antibody's intended target. In essence, a blocking peptide is used to block protein-antibody complex formation during immunochemical analysis. This makes it an invaluable tool for researchers aiming to validate antibody specificity and to elucidate the precise role of CD35 in various biological pathways.

Research has mapped epitopes for numerous monoclonal antibodies to CR1 (CD35), highlighting the complexity of this receptor and the need for precise tools like blocking peptides. For instance, a Mouse Monoclonal CD35 antibody or a Rabbit Recombinant Monoclonal CD35 antibody might be used in conjunction with the blocking peptide to confirm their specific binding to CD35. The CD35 blocking peptide is also crucial in studies investigating the role of complement receptors in diseases. For example, research into kidney diseases has explored blocking peptides and molecular mimicry as treatment for kidney conditions, suggesting potential therapeutic avenues where modulating complement receptor activity could be beneficial.

Furthermore, the CD35 blocking peptide can be utilized in various experimental setups. It is particularly useful in immunoblotting applications, where it can confirm the specificity of an antibody recognizing a protein of 210-220kDa, characteristic of CD35. It can also be used in antibody competition assays, as demonstrated by the CD35 Recombinant Protein Antigen which serves as a blocking peptide for NBP2-13872. The peptide's ability to block the action of specific antibodies makes it a versatile reagent for confirming the identity and specificity of CD35 in different sample types, including those from Human and Non-Human Primates.

The significance of CD35 extends to its role as a mature B-cell marker, labeling follicular dendritic reticulum cells and tumors derived from such cells. Therefore, a CD35 / CR1 (Follicular Dendritic Cell Marker) Monoclonal Antibody might be used in conjunction with the blocking peptide to study B-cell development and related malignancies. While the direct application of a CD35 blocking peptide in enhancing macrophage-mediated phagocytosis of tumor cells might not be as extensively documented as other blocking peptides like the CD24 / Siglec-10 blocking peptide, the fundamental principle of modulating immune responses through targeted blocking remains a key area of investigation. The ability of CD35 to mediate cellular binding of particles and immune complexes with activated complement means that blocking its function could have profound effects on phagocytosis and immune complex clearance.

In summary, the CD35 blocking peptide is an essential reagent for researchers investigating the complement system, immune cell function, and associated diseases. Its ability to specifically block the binding of anti-CD35 antibodies provides critical validation for experimental results, allowing for a deeper understanding of the multifaceted roles of CR1/CD35 in health and disease. The availability of various Monoclonal Cd35 Cr1 Antibody options, coupled with their corresponding blocking peptides, ensures that researchers have the necessary tools for rigorous immunological studies.